Ocular Therapeutix (OCUL) Successfully Appeals Patent Case Against Mati Therapeutics, Inc
FREE Breaking News Alerts from StreetInsider.com!
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Needham Starts NeoVolta (NEOV) at Buy
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Rockstar Games opens GTA VI pre-orders, priced at $79.99
- Rubio meets Gulf leaders, pledges security amid Iran deal doubts
Ocular Therapeutix (OCUL) PT Raised to $30 at JMP Securities
November 9, 2021 6:26 AM ESTJMP Securities analyst Jonathan Wolleben raised the price target on Ocular Therapeutix (NASDAQ: OCUL) to $30.00 (from $27.00) while maintaining a Market Outperform rating.... More
Ocular Therapeutix (OCUL) Tops Q3 EPS by 3c
November 8, 2021 4:34 PM ESTOcular Therapeutix (NASDAQ: OCUL) reported Q3 EPS of ($0.23), $0.03 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $12.15 million versus the consensus estimate of $12.45 million.
For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.
... MoreOcular Therapeutix (OCUL) Announces Update from Centers for Medicare and Medicaid Services for Reimbursement of DEXTENZA
November 5, 2021 9:01 AM EDTOcular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that the Centers for Medicare and Medicaid Services (CMS) released its final rules for the Outpatient Prospective Payment System (OPPS) and Medicare Physician Fee Schedule (MPFS) for 2022.
The OPPS final rule confirms that DEXTENZA will continue to be... More
